Results 61 to 70 of about 339,213 (296)

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy

Cancer Gene Therapy, 2020
Neuroendocrine (NE) tumors include a diverse spectrum of hormone-secreting neoplasms that arise from the endocrine and nervous systems. Current chemo- and radio-therapies have marginal curative benefits.
Yingnan Si, Seulhee Kim, Jianfa Ou, Yun Lu, Patrick Ernst, Kai Chen, J. Whitt, A. Carter, J. Markert, J. Bibb, Herbert Chen, Lufang Zhou, R. Jaskula-Sztul, X. Liu   +13 more
semanticscholar   +1 more source

High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi's sarcoma from Sardinia [PDF]

, 1998
A survey for antibodies to a recombinant small viral capsid antigen (sVCA) of human herpesvirus type 8 (HHV‐8) was conducted in Sardinia, one of the world's highest incidence areas for classic Kaposi's sarcoma (KS). Prevalence of antibodies to HHV‐8 sVCA
Angeloni, Antonio, Cerimele, Decio, Cottoni, Francesca Maria Giovanna, Faggioni, Alberto, Heston, Lee, Lin, Su-Fang, Masala, Maria Vittoria, Miller, George, Rigsby, Michael, Sirianni, Maria Caterina, Sun, Ren, Uccini, Stefania   +11 more
core   +1 more source

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Breast Cancer: Targets and Therapy, 2021
Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G ...
Linehan AS, Fitzpatrick OM, Morris PG
doaj  

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Liječnički vjesnik, 2023
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal ...
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić   +4 more
doaj   +1 more source

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Blood Cancer Journal, 2019
Interim analyses of a phase I study with GSK2857916, an antibody–drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM).
S. Trudel, N. Lendvai, R. Popat, P. Voorhees, B. Reeves, E. Libby, P. Richardson, A. Hoos, I. Gupta, V. Bragulat, Zangdong He, J. Opalinska, A. Cohen   +12 more
semanticscholar   +1 more source

Morphine activates neuroinflammation in a manner parallel to endotoxin [PDF]

, 2012
Opioids create a neuroinflammatory response within the CNS, compromising opioid-induced analgesia and contributing to various unwanted actions. How this occurs is unknown but has been assumed to be via classic opioid receptors.
A. A. Somogyi, A. J. de Jesus, A. Reddy, Barochia, Bevan, Bokhari, Dziarski, H. Yin, Hargreaves, Hoshino, Hutchinson, Hutchinson, Hutchinson, Hutchinson, Hutchinson, Hutchinson, J. Thomas, Jacquet, Joce, K. Cheng, K. Ramos, Kirikae, L. C. Loram, L. R. Watkins, Lewis, Li, Liu, Liu, M. R. Hutchinson, Manavalan, Milligan, Nagyoszi, Narita, Ohto, Park, Resman, Rice, Slivka, Takeuchi, Viriyakosol, Watkins, X. Wang, Youn   +42 more
core   +2 more sources

Application of Immuno-PET in Antibody–Drug Conjugate Development

Molecular Imaging, 2018
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective ...
Kendra S. Carmon PhD, Ali Azhdarinia PhD
doaj   +1 more source

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). [PDF]

PLoS ONE, 2015
The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung, Jang-Fang Kuo, Wan-Chen Wei, King-Jen Chang, Wei-Ting Chao   +4 more
doaj   +1 more source

Progresses in research and development of antibody-drug conjugate

生物医学转化, 2021
Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang, Fu Zhihao, Xu Gangling, Wang Wenbo, Yu Chuanfei, Wang Lan, Wang Junzhi   +6 more
doaj   +1 more source

Aptamer-based therapeutics and their potential in radiopharmaceutical design [PDF]

, 2007
Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications.
Ferreira, Catia S. M., Missailidis, Sotiris   +1 more
core   +3 more sources